Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Sep;42(9):1531-1537.
doi: 10.1007/s00296-022-05132-1. Epub 2022 Apr 25.

Tofacitinib monotherapy and erectile dysfunction in rheumatoid arthritis: a pilot observational study

Yusuf Karabulut  1 , Halise Hande Gezer  2 , Selin Esen  3 , İrfan Esen  4 , Ali Rıza Türkoğlu  5
Affiliations
Observational Study

Tofacitinib monotherapy and erectile dysfunction in rheumatoid arthritis: a pilot observational study

Yusuf Karabulut et al. Rheumatol Int. 2022 Sep.

Abstract

We aimed to explore the effect of tofacitinib on erectile dysfunction (ED), as well as disease activity and health related quality of life in male patients with rheumatoid arthritis (RA). Forty eight male RA patients with ED were included. Demographic and clinical data at baseline and 6 month of treatment were recorded from patients' medical records. Disease activity was evaluated with the disease activity score on 28 joints (DAS28), quality of life with Health Assessment Questionnaire-Disability Index (HAQ-DI) and ED with International Index of Erectile Function-5 (IIEF-5). The patients were aged 45.58 [Formula: see text] 2.14 years with a disease duration of 79.33 [Formula: see text] 25.31 months. According to the IIEF-5, 17 (35.4%) patients had severe ED, 10 (20.8%) patients moderate ED, 10 (20.8%) patients mild to moderate ED and 11 (22.9%) patients mild ED. For the entire patient group, baseline median IIEF-5 score was significantly increased from 9.35 (5.30-19.40) to 9.90 (5.20-24.90), baseline median DAS28 was significantly decreased from 5.65 (4.80-6.70) to 5.00 (2.40-6.40), HAQ-DI from 1.70 (1.10-2.40) to 1.15 (0.40-2.20) at 6th month of treatment (all p value < 0.001). Also, quantitative change in IIEF-5 was significantly correlated with changes in DAS28 (r: - 0.735, p < 0.001) and HAQ-DI (r: - 0.700, p < 0.001). Tofacitinib monotherapy may improve ED severity and as well as disease activity and health related quality of life in male patients with RA complaining of ED.

Keywords: Erectile dysfunction; Rheumatoid arthritis; Tofacitinib.

PubMed Disclaimer

References

    1. Rein P, Mueller RB (2017) Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatol Ther 4(2):247–261. https://doi.org/10.1007/s40744-017-0073-3 - DOI - PubMed - PMC
    1. Britto MT, Rosenthal SL, Taylor J, Passo MH (2000) Improving rheumatologists’ screening for alcohol use and sexual activity. Arch Pediatr Adolesc Med 154(5):478–483. https://doi.org/10.1001/archpedi.154.5.478 - DOI - PubMed
    1. Almeida PH, Castro Ferreira C, Kurizky PS, Muniz LF, Mota LM (2015) How the rheumatologist can guide the patient with rheumatoid arthritis on sexual function. Rev Bras Reumatol 55(5):458–463. https://doi.org/10.1016/j.rbr.2014.08.009 - DOI - PubMed
    1. Chen L, Shi GR, Huang DD, Li Y, Ma CC, Shi M, Su BX, Shi GJ (2019) Male sexual dysfunction: a review of literature on its pathological mechanisms, potential risk factors, and herbal drug intervention. Biomed Pharmacother 112:108585. https://doi.org/10.1016/j.biopha.2019.01.046 - DOI - PubMed
    1. Zhao S, Li E, Wang J, Luo L, Luo J, Zhao Z (2018) Rheumatoid arthritis and risk of sexual dysfunction: a systematic review and metaanalysis. J Rheumatol 45(10):1375–1382. https://doi.org/10.3899/jrheum.170956 - DOI - PubMed

Publication types

LinkOut - more resources